z-logo
open-access-imgOpen Access
Association of UGT1A1*6 , UGT1A1*28 , or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis
Author(s) -
Atasilp Chalirmporn,
Biswas Mohitosh,
Jinda Pimonpan,
Nuntharadthanaphong Nutthan,
Rachanakul Jiratha,
Hongkaew Yaowaluck,
Vanwong Natchaya,
Saokaew Surasak,
Sukasem Chonlaphat
Publication year - 2022
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.13277
Subject(s) - irinotecan , neutropenia , medicine , odds ratio , diarrhea , gastroenterology , cancer , toxicity , colorectal cancer
Effects of UGT1A1 *6 and UGT1A1 *28 genetic polymorphisms on irinotecan‐induced severe toxicities in Asian cancer patients are inconclusive. Also, ABCC2 c.3972C>T may affect toxicity of irinotecan. The aim was to assess the aggregated risk of neutropenia or diarrhea in Asian cancer patients taking irinotecan and inherited UGT1A1*6 , UGT1A1*28, or ABCC2 c.3972C>T genetic variants. A PubMed literature search for eligible studies was conducted. Odds ratios (ORs) were measured using RevMan software where p values <0.05 were statistically significant. Patients that inherited both UGT1A1*6 and UGT1A1*28 genetic variants (heterozygous: UGT1A1*1/*6  +  *1/*28 and homozygous: UGT1A1*6/*6  +  *28/*28 ) were significantly associated with increased risk of neutropenia and diarrhea compared to patients with UGT1A1*1/*1 (neutropenia: OR 2.89; 95% CI 1.97–4.23; p  < 0.00001; diarrhea: OR 2.26; 95% CI 1.71–2.99; p  < 0.00001). Patients carrying homozygous variants had much stronger effects in developing toxicities (neutropenia: OR 6.23; 95% CI 3.11–12.47; p  < 0.00001; diarrhea: OR 3.21; 95% CI 2.13–4.85; p  < 0.00001) than those with heterozygous variants. However, patients carrying the ABCC2 c.3972C>T genetic variant were not significantly associated with neutropenia (OR 1.67; 95% CI 0.98–2.84; p  = 0.06) and were significantly associated with a reduction in irinotecan‐induced diarrhea (OR 0.31; 95% CI 0.11–0.81; p  = 0.02). Asian cancer patients should undergo screening for both UGT1A1*6 and UGT1A1*28 genetic variants to reduce substantially irinotecan‐induced severe toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here